# Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

> **NCT00153803** · PHASE3 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 245 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Non-small Cell Lung Cancer
- NSCLC

## Interventions

- **DRUG:** Erlotinib (tarceva)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00153803
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00153803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00153803, "Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00153803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*